SC
RXRX icon

Syon Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Syon Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
33,399
+22,429
+204% +$74.7K 0.01% 938
2026
Q1 		$33.7K Buy
+10,970
New +$42.4K ﹤0.01% 904
2025
Q2 		– Sell
-22,150
Closed -$117K – 777
2025
Q1 		$117K Sell
22,150
-1,306
-6% -$9.52K 0.01% 569
2024
Q4 		$159K Buy
+23,456
New +$158K 0.01% 535

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Syon Capital's RXRX Position: Q2 2026 in Review

Syon Capital increased its Recursion Pharmaceuticals (RXRX) stake by 204% in Q2 2026, buying an estimated $74.7K and bringing the position to 33,399 shares worth $123K. The position accounts for 0.01% of the portfolio, ranked #938.

Syon Capital first reported a position in RXRX in Q4 2024 and has held it in 4 quarters since. The position peaked at $159K in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Syon Capital held 33,399 shares of Recursion Pharmaceuticals worth $123K as of Q2 2026.
  • Syon Capital bought 22,429 Recursion Pharmaceuticals shares in Q2 2026, an estimated $74.7K.
  • Recursion Pharmaceuticals made up 0.01% of Syon Capital's portfolio in Q2 2026, its #938 holding.
  • Syon Capital first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Syon Capital's Recursion Pharmaceuticals position peaked at $159K in Q4 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.